Does Medicare Cover GLP-1 Weight Loss Drugs in 2026?

Quick answer: Starting July 1, 2026, Medicare is covering GLP-1 weight loss drugs like Wegovy and Zepbound for the first time — at a $50/month copay — through a temporary program called the Medicare GLP-1 Bridge. You must be enrolled in a Part D plan and get prior authorization from your doctor to qualify.

If you or someone you know has been paying full price for a GLP-1 medication — or putting off asking about one because of the cost — this is genuinely significant news. For more than 20 years, federal law banned Medicare from covering prescription weight loss drugs outright. That ban is now being lifted, at least partially, starting this month.

Why Medicare Hasn’t Covered GLP-1s for Weight Loss Until Now

When Congress created Medicare Part D in 2003, it explicitly prohibited coverage for weight loss medications. That prohibition held for over two decades — even as GLP-1 drugs like Ozempic, Wegovy, and Zepbound became some of the most talked-about medical treatments in the country. Without insurance, these drugs can cost anywhere from $900 to over $1,300 per month at list price, putting them out of reach for many Medicare beneficiaries on fixed incomes.

Medicare has been able to cover some GLP-1 drugs for other approved indications — for example, Ozempic for Type 2 diabetes management, or Wegovy to reduce cardiovascular risk in adults with established heart disease. But coverage specifically for weight loss has been off the table, until now.

What the Medicare GLP-1 Bridge Program Actually Is

The Medicare GLP-1 Bridge is a short-term demonstration program run by the Centers for Medicare & Medicaid Services (CMS). It begins July 1, 2026 and runs through December 31, 2027. During that window, eligible Medicare Part D beneficiaries can access certain GLP-1 weight loss medications at a flat $50 per month copay — a significant reduction from the $900–$1,300 list prices most people have been facing.

Which Drugs Are Covered?

The Bridge covers three specific medications prescribed specifically for weight loss:

Ozempic is not included in the Bridge program — even though it contains the same active ingredient as Wegovy (semaglutide). That’s because Ozempic is FDA-approved for Type 2 diabetes, not weight loss, and the Bridge specifically covers drugs with a weight loss indication. If you’re on Ozempic for diabetes management, that’s handled through your regular Part D plan.

Who Qualifies?

To access the Medicare GLP-1 Bridge, you must:

• Be enrolled in a Medicare Part D standalone prescription drug plan (PDP) or a Medicare Advantage plan with drug coverage (MAPD)
• Have a qualifying diagnosis — generally obesity (BMI of 30 or higher), or overweight (BMI of 27 or higher) with at least one weight-related condition such as hypertension, cardiovascular disease, or obstructive sleep apnea
• Receive prior authorization from your doctor, submitted to CMS’s central processor

How the Prior Authorization Process Works

Unlike standard Part D claims, this program runs through a single CMS central processor rather than your individual plan. Here’s how it flows:

1. Your doctor submits a prior authorization request and prescription to the CMS central processor
2. The processor reviews documentation to confirm you meet the eligibility criteria
3. Once approved, the processor pays the claim and the pharmacy releases your medication
4. You pay your $50 copay at the pharmacy

What About After December 2027?

The Bridge is explicitly a temporary demonstration program — it ends December 31, 2027. CMS has announced a longer-term program called the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) that was originally planned to begin in January 2027, though in April 2026 CMS announced a delay to the Part D portion of that program. The exact timeline and structure of what comes after the Bridge is still being finalized.

What this means practically: if you start a GLP-1 medication through the Bridge and want to ensure continued coverage going into 2028 and beyond, pay close attention to which Part D plans offer GLP-1 coverage during the next Open Enrollment Period (October 15 – December 7). Plans that participate in the BALANCE Model, whenever it launches, will be the ones to watch.

What Should You Do Now?

If you’re on Medicare and interested in a GLP-1 medication for weight management, here are the practical next steps:

• Talk to your doctor — they need to submit the prior authorization, so start the conversation now rather than waiting
• Confirm your Part D enrollment — you must be enrolled in a qualifying Part D or MAPD plan to participate
• Watch Open Enrollment in October — review your Part D plan’s GLP-1 coverage for 2027 during the October 15 – December 7 window, since coverage rules may shift when the Bridge ends
• Don’t use discount cards alongside Medicare — federal law prohibits using manufacturer copay coupons or programs like TrumpRx when you’re on a government program like Medicare